La Jolla, California-based MediciNova (Nasdaq: MNOV) received a Notice of Allowance from the US Patent and Trademark Office for a method-of-treatment patent covering ibudilast (MN-166) in combination with an anti-PD-1 immune checkpoint inhibitor for glioblastoma treatment. The allowed claims span dosing regimen, route of administration, dosing frequency, dose levels, and duration of therapy, and are written broadly enough to encompass multiple anti-PD-1 antibodies rather than a single agent. Once formally issued, the patent is expected to expire no earlier than September 2042, providing MediciNova with a method-patent exclusivity runway of approximately 16 years in the US for this combination approach.
The commercial significance is primarily strategic rather than immediately revenue-generating: MediciNova has not disclosed active Phase II or Phase III glioblastoma trial data, and ibudilast remains a known compound without composition-of-matter protection in this context. The allowance establishes intellectual property protection around the use of ibudilast with anti-PD-1 inhibitors in glioblastoma, which could support future partnership or licensing discussions if clinical evidence emerges.
Ibudilast is a small-molecule inhibitor of phosphodiesterase type 4 (PDE4) and macrophage migration inhibitory factor (MIF), a pro-inflammatory cytokine implicated in immunosuppressive signaling within the tumor microenvironment. In glioblastoma, the tumor microenvironment is heavily immunosuppressive, characterized by M2-polarized tumor-associated macrophages and microglia that blunt T-cell activity. The mechanistic premise of the MN-166 combination therapy is that ibudilast’s suppression of MIF and modulation of PDE4-driven inflammatory signaling may remodel the immunosuppressive microenvironment, potentially augmenting the efficacy of anti-PD-1 checkpoint blockade by improving T-cell infiltration and activity at the tumor site.
This rationale positions ibudilast as a tumor microenvironment modulator rather than a direct cytotoxic or immunostimulatory agent, distinguishing it mechanistically from conventional chemotherapy combinations with checkpoint inhibitors. Specific clinical results from MediciNova’s glioblastoma program remain undisclosed.